The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins
Abstract
BACKGROUND: Epidemiologic and biochemical evidence suggest a role of statins and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as anti-neoplastic agents. This study was designed to evaluate the association between the use of these agents and the risk of breast cancer recurrence. METHODS: We reviewed the medical records of patients treated for stage II/III breast cancer between 1999 and 2005. Statin and ACE-inhibitors/ARB users were defined as patients who took these medications for at least 6 months in no evidence of disease (NED) stage after the initial diagnosis. The primary outcome was disease-free survival and the secondary was overall survival. The Kaplan-Meier and Cox proportional hazard models were used. RESULTS: A total of 703 patients were included. The median and maximal of follow up was 55 and 118 months, respectively. A total of 168 patients used ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both. Univariate analysis showed significant reduction in breast cancer recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio (HR) = 0.57; 95% CI: 0.37-0.89; p = .013) or statins (HR = 0.43; 95% CI: 0.26-0.70; p < .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31-0.76; p = .002) and statins (HR = 0.40; 95% CI: 0.24-0.67; p < .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15-0.61; p = .001). No association was found regarding overall survival. CONCLUSIONS: The use of ACE-inhibitors/ARBs, statins, and the combination of both were all associated with a reduced risk of breast cancer recurrence. This observation should prompt further exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Kwan, M. L., Habel, L. A., Flick, E. D., Quesenberry, C. P., & Caan, B. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9683-8 · Cited by 175
Cited by
Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
Ma, X., Bi, E., Lu, Y., Su, P., Huang, C., Liu, L., Wang, Q., Yang, M., Kalady, M. F., Qian, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.002 · Cited by 1,033
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
The interplay between cell signalling and the mevalonate pathway in cancer
Mullen, P. J., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.76 · Cited by 699
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
Verhoest, G., Dolley-Hitze, T., Jouan, F., Belaud-Rotureau, M.-A., Oger, E., Lavenu, A., Bensalah, K., Arlot-Bonnemains, Y., Collet, N., Rioux-Leclercq, N., et al. (2014) · BioMed Research International · doi:10.1155/2014/901371 · Cited by 260
Metadata
- Authors
- Chae, Y. K., Valsecchi, M. E., Kim, J., Bianchi, A. L., Khemasuwan, D., Desai, A., & Tester, W.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2011-09-21
- Volume
- 29
- Issue
- 9
- Pages
- 585-593
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2114927900
- Cited by
- 174
- References
- 2
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins. https://app.cochat.ai/papers/10.3109/07357907.2011.616252
- The paper
- Chae, Y. K., Valsecchi, M. E., Kim, J., Bianchi, A. L., Khemasuwan, D., Desai, A., & Tester, W. (2011). Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins. Cancer Investigation. https://doi.org/10.3109/07357907.2011.616252
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.